Nexalin Technology shares are trading higher after the company on Thursday announced a patent by the USPTO related to its deep intracranial frequency stimulation device for the treatment of Alzheimer's and dementia.
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology shares are trading higher following the announcement of a new patent by the USPTO for its deep intracranial frequency stimulation device aimed at treating Alzheimer's and dementia.
June 21, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's stock is experiencing an upward trend after the company announced a new patent for its deep intracranial frequency stimulation device, which targets Alzheimer's and dementia treatment.
The announcement of a new patent is a significant milestone for Nexalin Technology, indicating potential future revenue streams and market expansion in the healthcare sector. This positive development is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100